FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3096233695> ?p ?o ?g. }

• W3096233695 abstract "Angiotensin-converting enzyme (ACE) inhibitors are frequently used to treat hypertension and congestive heart failure. Preclinical data show that ACE plays a role on both innate and adaptive immune responses. Since interactions between ACE inhibitors and immune checkpoint inhibitors (ICIs) have not been reported, the aim of this study is to investigate the influence of ACE inhibitors on non-small cell lung cancer (NSCLC) patients treated with programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) inhibitors. We conducted a retrospective cohort analysis of NSCLC patients treated with PD-1/PD-L1 inhibitors. Clinical and co-medication data as well as tumor biopsies were collected. Groups were defined according to patients’ co-medications at the time of ICI initiation. Among the 178 patients included, 22 (13.1%) received ACE inhibitors. While baseline characteristics were similar in both groups, ACE inhibitors group had a shorter median PFS (Progression-Free Survival) compared to the control group: 1.97 vs. 2.56 months, p = .01 (HR = 1.8 CI95% 1.1–2.8). Using CIBERSORT, RNA sequencing suggested that tumors from the ACE inhibitors group had less M1 macrophages, activated mast cells, NK cells and memory activated T cells, thus suggesting an immunosuppressed state. In vitro, the ACE inhibitor, captopril, induced M2 marker at the cell surface of monocytes engaged into M1 differentiation. Thus, ACE inhibitors prescription concomitant to PD-1/PD-L1 inhibitors treatment seems to be associated with impaired outcome and with a tumor immunosuppressed state in patients with advanced NSCLC. These results should be validated in larger prospective cohorts." @default.
• W3096233695 created "2020-11-09" @default.
• W3096233695 creator A5010144431 @default.
• W3096233695 creator A5011315376 @default.
• W3096233695 creator A5015151938 @default.
• W3096233695 creator A5016814827 @default.
• W3096233695 creator A5018585640 @default.
• W3096233695 creator A5031826036 @default.
• W3096233695 creator A5035290049 @default.
• W3096233695 creator A5043463827 @default.
• W3096233695 creator A5045766235 @default.
• W3096233695 creator A5074294227 @default.
• W3096233695 date "2020-01-01" @default.
• W3096233695 modified "2023-10-17" @default.
• W3096233695 title "Angiotensin-converting enzyme (ACE) inhibitor prescription affects non-small-cell lung cancer (NSCLC) patients response to PD-1/PD-L1 immune checkpoint blockers" @default.
• W3096233695 cites W136329886 @default.
• W3096233695 cites W1985987855 @default.
• W3096233695 cites W1987586914 @default.
• W3096233695 cites W2035105999 @default.
• W3096233695 cites W2049553585 @default.
• W3096233695 cites W2052854029 @default.
• W3096233695 cites W2076362159 @default.
• W3096233695 cites W2077999719 @default.
• W3096233695 cites W2082573645 @default.
• W3096233695 cites W2092700573 @default.
• W3096233695 cites W2104347254 @default.
• W3096233695 cites W2116846792 @default.
• W3096233695 cites W2124761610 @default.
• W3096233695 cites W2179438025 @default.
• W3096233695 cites W2222086386 @default.
• W3096233695 cites W2291298003 @default.
• W3096233695 cites W2317340981 @default.
• W3096233695 cites W2323326409 @default.
• W3096233695 cites W2522313999 @default.
• W3096233695 cites W2599658522 @default.
• W3096233695 cites W2616568877 @default.
• W3096233695 cites W2635951006 @default.
• W3096233695 cites W2655262992 @default.
• W3096233695 cites W2748524892 @default.
• W3096233695 cites W2750028600 @default.
• W3096233695 cites W2779221466 @default.
• W3096233695 cites W2792274845 @default.
• W3096233695 cites W2792523078 @default.
• W3096233695 cites W2796582438 @default.
• W3096233695 cites W2888599070 @default.
• W3096233695 cites W2889459498 @default.
• W3096233695 cites W2893501833 @default.
• W3096233695 cites W2897283341 @default.
• W3096233695 cites W2902568381 @default.
• W3096233695 cites W2902684675 @default.
• W3096233695 cites W2903708727 @default.
• W3096233695 cites W2913722925 @default.
• W3096233695 cites W2914335731 @default.
• W3096233695 cites W2916451481 @default.
• W3096233695 cites W2918511688 @default.
• W3096233695 cites W2943492451 @default.
• W3096233695 cites W2955224282 @default.
• W3096233695 cites W2988734364 @default.
• W3096233695 doi "https://doi.org/10.1080/2162402x.2020.1836766" @default.
• W3096233695 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7595630" @default.
• W3096233695 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33178495" @default.
• W3096233695 hasPublicationYear "2020" @default.
• W3096233695 type Work @default.
• W3096233695 sameAs 3096233695 @default.
• W3096233695 citedByCount "14" @default.
• W3096233695 countsByYear W30962336952021 @default.
• W3096233695 countsByYear W30962336952022 @default.
• W3096233695 countsByYear W30962336952023 @default.
• W3096233695 crossrefType "journal-article" @default.
• W3096233695 hasAuthorship W3096233695A5010144431 @default.
• W3096233695 hasAuthorship W3096233695A5011315376 @default.
• W3096233695 hasAuthorship W3096233695A5015151938 @default.
• W3096233695 hasAuthorship W3096233695A5016814827 @default.
• W3096233695 hasAuthorship W3096233695A5018585640 @default.
• W3096233695 hasAuthorship W3096233695A5031826036 @default.
• W3096233695 hasAuthorship W3096233695A5035290049 @default.
• W3096233695 hasAuthorship W3096233695A5043463827 @default.
• W3096233695 hasAuthorship W3096233695A5045766235 @default.
• W3096233695 hasAuthorship W3096233695A5074294227 @default.
• W3096233695 hasBestOaLocation W30962336951 @default.
• W3096233695 hasConcept C121608353 @default.
• W3096233695 hasConcept C126322002 @default.
• W3096233695 hasConcept C143998085 @default.
• W3096233695 hasConcept C203014093 @default.
• W3096233695 hasConcept C27016395 @default.
• W3096233695 hasConcept C2776256026 @default.
• W3096233695 hasConcept C2777701055 @default.
• W3096233695 hasConcept C2779384505 @default.
• W3096233695 hasConcept C2779479957 @default.
• W3096233695 hasConcept C2779611605 @default.
• W3096233695 hasConcept C2781053074 @default.
• W3096233695 hasConcept C502942594 @default.
• W3096233695 hasConcept C71924100 @default.
• W3096233695 hasConcept C84393581 @default.
• W3096233695 hasConcept C8891405 @default.
• W3096233695 hasConcept C98274493 @default.
• W3096233695 hasConceptScore W3096233695C121608353 @default.
• W3096233695 hasConceptScore W3096233695C126322002 @default.
• W3096233695 hasConceptScore W3096233695C143998085 @default.
• W3096233695 hasConceptScore W3096233695C203014093 @default.

• next